Deutsche Bank Ag\ Nuvation Bio Inc. Transaction History

Deutsche Bank Ag\

$218 Billion
Q2 2024

A detailed history of Deutsche Bank Ag\ transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 72,329 shares of NUVB stock, worth $159,847. This represents 0.0% of its overall portfolio holdings.

Number of Shares

72,329

Previous 85,859 15.76%

Holding current value

$159,847

Previous $312,000 32.37%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.58 - $3.69 $34,907 - $49,925	-13,530 Reduced 15.76%	72,329 $211,000
Q1 2024 May 15, 2024	BUY	$1.46 - $3.97 $6,121 - $16,646	4,193 Added 5.13%	85,859 $312,000
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.53 $2,969 - $4,732	-3,093 Reduced 3.65%	81,666 $123,000
Q3 2023 Nov 09, 2023	BUY	$1.26 - $2.1 $20,602 - $34,337	16,351 Added 23.9%	84,759 $113,000
Q2 2023 Aug 14, 2023	SELL	$1.56 - $1.84 $3,101 - $3,657	-1,988 Reduced 2.82%	68,408 $123,000
Q1 2023 May 15, 2023	SELL	$1.6 - $2.48 $8,278 - $12,831	-5,174 Reduced 6.85%	70,396 $116,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $2.5 $47,569 - $70,787	28,315 Added 59.92%	75,570 $145,000
Q3 2022 Nov 14, 2022	SELL	$0.29 - $4.04 $5,112 - $71,229	-17,631 Reduced 27.17%	47,255 $106,000
Q2 2022 Aug 11, 2022	SELL	$3.24 - $5.85 $118,580 - $214,104	-36,599 Reduced 36.06%	64,886 $210,000
Q1 2022 May 13, 2022	SELL	$4.6 - $8.83 $28,018 - $53,783	-6,091 Reduced 5.66%	101,485 $534,000
Q4 2021 Feb 11, 2022	BUY	$7.75 - $10.05 $479,639 - $621,984	61,889 Added 135.46%	107,576 $914,000
Q3 2021 Nov 04, 2021	BUY	$7.78 - $10.0 $157,599 - $202,570	20,257 Added 79.66%	45,687 $454,000
Q2 2021 Aug 11, 2021	BUY	$9.22 - $14.48 $234,464 - $368,226	25,430 New	25,430 $236,000

Others Institutions Holding NUVB

# of Institutions

152

Shares Held

123M

Call Options Held

9.7K

Put Options Held

6.5K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account